<DOC>
	<DOCNO>NCT02909166</DOCNO>
	<brief_summary>The aim study find whether aliskiren reduces atrial fibrillation burden measure pacemaker device</brief_summary>
	<brief_title>Role ALiskiren , Direct Renin Inhibitor , Preventing Atrial Fibrillation Patients With Pacemaker ; RALF .</brief_title>
	<detailed_description>The aim study find effect direct renin inhibitor , aliskiren , reduction AF patient pacemaker due sinus node disease paroxysmal atrial fibrillation . Hypothesis possibility reduce atrial remodel due AF also enhance atrial reverse remodel aliskiren . The effect aliskiren total AF burden evaluate pacemaker 's memory storage . The main purpose study find new safe drug treatment target reduce AF recurrence related complication pacemaker patient . Also aim evaluate feasibility modern highly sophisticated pacemaker system evaluation drug treatment AF reduction .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>age 18 85 year sinus node disease paroxysmal AF provide sign informed consent accord Declaration Helsinki study participation previously implanted St. Jude Medical Identity / Victory / Zephyr ADX new model SJM DDDR pacemaker ability record high atrial rate contraindication use aliskiren severe impairment renal function ( serum creatinine &gt; 160 µmol/L ) patient solitary kidney renal transplant renal artery stenosis significant know aortic mitral valve stenosis obstructive hypertrophic cardiomyopathy hypersensitivity aliskiren excipients concomitant treatment cyclosporine patient uncontrolled hypertension require treatment hypertension systolic blood pressure measure two separate occasion ≥ 160 mmHg diastolic blood pressure two separate occasion ≥ 100 mmHg absolute indication use RAAS blocker chronic , persist AF ( persist AF screen ≥ 4 cardioversions perform beforehand ) sit systolic arterial blood pressure le 100 mm Hg time randomisation need ventricular pace 30 % enrolment pregnancy and/or lactation woman childbearing potential ( postmenopausal woman woman tubal ligation allow ) serious disease expect cause substantial deterioration patient 's health next two year past present alcohol drug abuse participation clinical trial last three month suspicion poor study compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>